Mapping glioblastoma in three dimensions (3D) reveals marked epigenomic intratumoral heterogeneity (ITH), researchers have reported.
Treatment failure in glioblastoma is often attributed to ITH as it facilitates the selection of resistant clones, according to Dr Radhika Mathur of the University of California San Francisco, USA. However, the extent of epigenomic ITH has not been established.
Therefore, Dr Mathur and colleagues developed a novel topographical approach to characterizing epigenomic ITH in 3D. They defined the tumor volume using preoperative MRI scans, and then acquired multiple samples intraoperatively.